CHICAGO — New research presented Sunday at the Endocrine Society’s annual meeting is forcing a strategic recalculation of how doctors and patients view hormone replacement therapy. The study, unveiled at ENDO 2026 in Chicago, found that postmenopausal women using hormonal therapy had a 69% lower risk of low bone mineral density in the spine and hip. Those are precisely the areas where older women most frequently suffer fractures.
The broader stakes here are significant. Osteoporosis and weakening bones have long been accepted as an almost inevitable cost of aging for many women.
This data signals that a therapy many have been reluctant to use may offer a powerful shield. Of the 387 postmenopausal women in the study who underwent DEXA scans to measure bone density between 2021 and 2025, 33% were using hormonal therapy. The other 67% were not.
The findings were the same even after researchers adjusted for other variables. For years, the calculus around HRT shifted sharply against its use.
Increased concerns about breast and ovarian cancer caused many menopausal women to avoid it altogether. Later studies, however, have shown the benefits outweigh the risks. “This study revisits that narrative and shows that menopausal hormone therapy may have an important added benefit: protecting bone health,” lead study author Diego Espinoza-Peralta, vice president of the Mexican Society of Nutrition and Endocrinology, said in a press release.
“That shifts the conversation from ‘avoid if possible’ to ‘reconsider in the right patient’,” he added. Strategically, this reframes the conversation for millions of women navigating menopause. Hot flashes, night sweats, and fatigue are the immediate battles.
But the quiet threat of low bone density — and the fractures and disability that follow — is what this research targets. The findings present a clear choice.
Women not using hormonal therapy face a greater chance of developing osteoporosis. Those on the therapy saw a reduced risk. What this signals for clinicians is a need to re-engage with patients on a therapy many have written off.
The data from ENDO 2026 is a direct challenge to the prevailing reluctance. The study’s authors are not making a blanket recommendation.
The language is careful: “reconsider in the right patient.” But the numbers are stark. A 69% reduction in risk is not a marginal gain. It is a strategic advantage in the long-term fight for bone health. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Menopause therapy cuts low bone density risk by 69%”, “description”: “CHICAGO — New research presented Sunday at the Endocrine Society’s annual meeting is forcing a strategic recalculation of how doctors and patients view hormone replacement…”, “datePublished”: “2026-06-28 18:00:41T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
